

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Foresight Diagnostics Inc.,
Petitioner,

v.

Personalis, Inc.,
Patent Owner

Case No. IPR2023-00545
U.S. Patent No. 11,299,783

PETITIONER 'S CORRECTED EXHIBIT LIST

Mail Stop: PATENT BOARD
Patent Trial and Appeal Board
U.S. Patent & Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

CORRECTED PETITIONER'S EXHIBIT LIST

Ex. 1001	U.S. Patent No. 11,299,783 to West <i>et al.</i>
Ex. 1002	Rebecca J. Leary <i>et al.</i> , “Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing,” <i>Science Translational Medicine</i> (2010) (Leary)
Ex. 1003	Quake <i>et al.</i> , WO 2011/057061 (Quake)
Ex. 1004	Matthew W. Anderson & Iris Schrijver, “Next Generation DNA Sequencing and the Future of Genomic Medicine,” <i>Genes</i> (2010) (Anderson)
Ex. 1005	Andreas Gnirke <i>et al.</i> , “Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing,” <i>Nature Biotechnology</i> (2009) (Gnirke)
Ex. 1006	Florian Mertes <i>et al.</i> , “Targeted enrichment of genomic DNA regions for next-generation sequencing, Briefings in Functional Genomics,” <i>Briefings in Functional Genomics</i> (2011) (Mertes)
Ex. 1007	Lira Mamanova <i>et al.</i> , “Target-enrichment strategies for next-generation sequencing,” <i>Nature</i> (2010) (Mamanova)
Ex. 1008	K.C. Allen Chan <i>et al.</i> , “Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing,” <i>Clinical Chemistry</i> (2013) (Chan)
Ex. 1009	Gary J.W. Liao <i>et al.</i> , “Targeted Massively Parallel Sequencing of Maternal Plasma DNA Permits Efficient and Unbiased Detection of Fetal Alleles,” <i>Clinical Chemistry</i> (2011) (Liao)
Ex. 1010	<i>Personalis v. Foresight</i> , First Amended Complaint, D. Colo., Case No. 1:22-v-01913, Dkt. 9, filed August, 17, 2022 (“FAC”)
Ex. 1011	Reserved

Ex. 1012	Timothy J. Ley <i>et al.</i> , “DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome,” <i>Nature</i> (2008) (Ley)
Ex. 1013	Jay Shendure & Hanlee Ji, “Next-generation DNA sequencing,” <i>Nature Biotechnology</i> (2008) (Shendure)
Ex. 1014	Jeffrey S. Ross and Maureen Cronin, “Whole Cancer Genome Sequencing by Next-Generation Methods,” <i>American Journal of Clinical Pathology</i> (2011) (Ross)
Ex. 1015	David J. McBride, et al., “Use of Cancer-Specific Genomic Rearrangements to Quantify Disease Burden in Plasma from Patients with Solid Tumors,” <i>Genes, Chromosomes & Cancer</i> (2010) (McBride)
Ex. 1016	David M. Kurtz, et al., “Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA,” <i>Nature Biotechnology</i> (2021) (Kurtz) (Ex. J to FAC)
Ex. 1017	https://www.aacc.org/science-and-research/clinical-chemistry/clinical-chemistry-podcasts/2013/cancer-genome-scanning-in-plasma-detection-of-tumor-associated-copy-number-aberrations
Ex. 1018	NIH Spreadsheet Regarding DNA Sequencing Costs
Ex. 1019	https://www.genome.gov/about-genomics/fact-sheets/DNA-Sequencing-Costs-Data
Ex. 1020	Declaration of John Quackenbush, Ph.D.
Ex. 1021	Reserved
Ex. 1022	Reserved
Ex. 1023	<i>Curriculum Vitae</i> of John Quackenbush
Ex. 1024	https://www.garvan.org.au/research/kinghorn-centre-for-clinical-genomics/learn-about-genomics/for-gp/genetics-refresher-1/types-of-variants

Ex. 1025	Seo Young Oh, et al., “Improved DNA Extraction Method for Molecular Diagnosis from Smaller numbers of Cells,” <i>Korean Journal of Clinical Laboratory Science</i> (2014) (Oh)
Ex. 1026	Leary Supplemental Information
Ex. 1027	Hugo Lam, et al., “Performance comparison of whole-genome sequencing platforms,” <i>Nature Biotechnology</i> (2012) (Lam)
Ex. 1028	Illumina, Technical Note: Sequencing
Ex. 1029	Illumina, Specification Sheet: Illumina Sequencing
Ex. 1030	Tim Forshew, et al., “Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA,” <i>Science Translational Medicine</i> (2012) (Forshew)
Ex. 1031	Matthew Meyerson, et al., “Advances in understanding cancer genomes through second-generation sequencing,” <i>Nature Reviews</i> (2010) (Meyerson)
Ex. 1032	Reserved
Ex. 1033	Reserved
Ex. 1034	Reserved
Ex. 1035	Reserved
Ex. 1036	Reserved
Ex. 1037	Reserved
Ex. 1038	Reserved
Ex. 1039	Reserved
Ex. 1040	D. Sims <i>et al.</i> , “Sequencing depth and coverage: key considerations in genomic analyses,” <i>Nature Reviews: Genetics</i> (2014) (Sims)

Ex. 1041	H. Li, “Mapping short DNA sequencing reads and calling variants using mapping quality scores,” <i>Genome Res.</i> (2008) (Li)
Ex. 1042	Ley Supplemental Information
Ex. 1043	A. Newman <i>et al.</i> , “Integrated digital error suppression for improved detection of circulating tumor DNA,” <i>Nature Biotechnology</i> (2016) (Newman)
Ex. 1044	A. Newman <i>et al.</i> , “An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage,” <i>Nature Medicine</i> (2014) (Newman 2014)
Ex. 1045	Newman Supplementary Excel Spreadsheet
Ex. 1046	M. Clark <i>et al.</i> , “Performance comparison of exome DNA sequencing technologies,” <i>Nature Biotechnology</i> (2011) (Clark)
Ex. 1047	Illumina MiSeq Worksheet (2015)
Ex. 1048	Genbank Record for CDH24
Ex. 1049	Genbank Record for SLC15A1
Ex. 1050	Genbank Record for KNDC1
Ex. 1051	Genbank Record for PTPRT
Ex. 1052	Genbank Record for GRINL1B
Ex. 1053	Genbank Record for ADGRA1 (GPR123)
Ex. 1054	Genbank Record for GPR183 (EBI2)
Ex. 1055	Genbank Record for CDHR2 (PCLKC)
Ex. 1056	Genbank Record for FLT3
Ex. 1057	Genbank Record for NPM1
Ex. 1058	Genbank Record for BRCA2

Ex. 1059	Genbank Record for TP53
Ex. 1060	Reserved
Ex. 1061	Reserved
Ex. 1062	Reserved
Ex. 1063	Reserved
Ex. 1064	Reserved
Ex. 1065	Reserved
Ex. 1066	Reserved
Ex. 1067	Reserved
Ex. 1068	Reserved
Ex. 1069	Reserved
Ex. 1070	S. Dawson, <i>et al.</i> , “Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer,” New England Journal of Medicine (2013) (Dawson)
Ex. 1071	R. Burrell, <i>et al.</i> , “The causes and consequences of genetic heterogeneity in cancer evolution,” Nature (2013) (Burrell)
Ex. 1072	Plaintiff Personalis’ Infringement Contentions for United States Patent 11,299,783
Ex. 1073	C. Haferlach, <i>et al.</i> , “Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype,” Leukemia (2008)
Ex. 1074	S. Misawa, <i>et al.</i> , “Significance of chromosomal alterations and mutations of the N-RAS and TP53 genes in relation to leukemogenesis of acute myeloid leukemia,” Leukemia Research (1998) (Misawa)

Ex. 1075	S. Davies, <i>et al.</i> , “Indications for Hematopoietic Cell Transplantation in Acute Leukemia,” <i>Biology of Blood and Marrow Transplantation</i> (2008) (<i>Davies</i>)
Ex. 1076	B. Alter, <i>et al.</i> , “Clinical and molecular features associated with biallelic mutations in <i>FANCD1/BRCA2</i> ,” <i>Journal of Medical Genetics</i> (2007) (<i>Alter</i>)
Ex. 1077	D. Bentley, <i>et al.</i> , “Accurate whole human genome sequencing using reversible terminator chemistry,” <i>Nature</i> (2008) (<i>Bentley</i>)

Dated: February 22, 2023

Respectfully submitted,

/Andrew E. Krause/

Andrew E. Krause (Reg. No. 76,276)
IRELL & MANELLA LLP

Amir Naini (Reg. No. 45,770)
NAINI P.C.

Attorneys for Petitioner
Foresight Diagnostics Inc.

CERTIFICATE OF SERVICE

I hereby certify, pursuant to 37 C.F.R. section 42.6, that on February 22, 2023, a complete copy of **PETITIONER 'S CORRECTED EXHIBIT LIST** was served upon the following, by ELECTRONIC MAIL:

Davin Stockwell
dstockwell@orrick.com
ORRICK, HERRINGTON & SUTCLIFFE LLP (Personalis)
IP Prosecution
2050 Main Street, Suite 1100
IRVINE, CA 92614
UNITED STATES

Courtesy copies were also sent to Patent Owner's counsel of record in the related district court litigation at the following addresses:

edward.reines@weil.com
derek.walter@weil.com
nate.ngerebara@weil.com

By: /Pia S. Kamath/
Pia S. Kamath